Skip to main content
Signal8

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

$GILDPress releaseJun 8, 2026, 4:35 PM ETRead the release

Gilead and Merck announced that the primary efficacy endpoint was met in both Phase 3 ISLEND-1 and ISLEND-2 trials for the investigational once-weekly oral HIV regimen of islatravir/lenacapavir. The combination was found to be statistically non-inferior to BIKTARVY in ISLEND-1 and to standard of care daily oral antiretroviral therapy in ISLEND-2, with a comparable safety profile.

Key figures

Drug Name
Islatravir/Lenacapavir
Phase Of Trial
Phase 3
Trial names
["ISLEND-1","ISLEND-2"]
Islatravir dose
2 mg
Dosing frequency
once-weekly
Lenacapavir dose
300 mg
Primary endpoint met
Yes

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.